ArticleEndocrine oncology (Bristol, England)2025
Gastric neuroendocrine neoplasms: analysis of a cohort of patients followed at the Brazilian National Cancer Institute.
Article in Endocrine oncology (Bristol, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Gastric neuroendocrine neoplasms (G-NENs) are rare tumors categorized into subtypes, each exhibiting unique characteristics, levels of aggressiveness and prognostic implications. This study aimed to describe the experience on G-NEN management at the Brazilian National Cancer Institute. Methods: Retrospective analysis involving all patients diagnosed with G-NEN from July 2000 to October 2022. Results: 116 patients with G-NEN were identified; histopathological classification was possible in only 97 patients. Of these, 85 (87.6%) cases were of gastric neuroendocrine tumors (G-NETs) and 12 (12.4%) cases were of gastric neuroendocrine carcinoma (NEC). According to the WHO classification, 51 were classified as NET-G1, 31 as NET-G2, three as NET-G3 and 12 as NEC. Among the G-NETs, type 1 was most prevalent with 60 cases, followed by type 3 (eleven cases) and type 2 (five cases). Nonmetastatic patients were initially treated with endoscopic resection (59 patients), endoscopic surveillance (18 patients) and upfront surgical intervention (18 patients). For metastatic cases, treatment regimens included platinum-based chemotherapy, somatostatin analogs, peptide receptor radionuclide therapy and palliative surgical options. The median overall survival was 84.5 months for NET-G1, 73.4 months for NET-G2, 17.4 months for NET-G3 and 6.2 months for NEC. Conclusion: This report presents the largest cohort of G-NEN in Brazil. While type 1 small G-NET generally exhibits indolent behavior, NEC is characterized by extreme aggressiveness. The survival outcomes observed in this treated population align with those reported in oncology centers from higher-income regions. This underscores the necessity for establishing reference centers dedicated to neuroendocrine tumors in low- to middle-income countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.